Santhera Receives Negative Opinion from the CHMP for its Marketing Authorization Application for Raxone® in DMD and Intends to Appeal this Opinion
(Thomson Reuters ONE) -
Santhera Pharmaceuticals Holding AG /
Santhera Receives Negative Opinion from the CHMP for its Marketing Authorization
Application for Raxone® in DMD and Intends to Appeal this Opinion
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Liestal, Switzerland, September 15, 2017 - Santhera Pharmaceuticals (SIX: SANN)
announces that the Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency (EMA) has adopted a negative opinion for its Type II
extension application for Raxone(®) (idebenone) in Duchenne muscular dystrophy
(DMD). Santhera plans to appeal the opinion and will seek a re-examination by
the CHMP.
Santhera gave its oral explanation to the CHMP on Wednesday this week to further
support the clinical relevance of the existing data in the proposed indication.
The CHMP expressed uncertainties whether the phase III DELOS trial provides
sufficient evidence of efficacy to allow a Type II variation of Santhera's
existing marketing authorization for Raxone.
"We are surprised and disappointed by the opinion of the CHMP. Data from the
phase III DELOS trial demonstrated statistically significant and clinically
relevant evidence that Raxone slows the decline of respiratory function, and
reduces the risk of bronchopulmonary complications and hospitalization in
patients with DMD not using glucocorticoids," said Thomas Meier, PhD, CEO of
Santhera. "These patients in the respiratory decline stage currently have no
treatment options, and because we are confident that they could benefit from
treatment with Raxone, we plan to appeal this opinion and seek re-examination."
The application was filed as a Type II Variation of the existing marketing
authorization for Leber's hereditary optic neuropathy (LHON), and is based on
data from Santhera's phase II (DELPHI) study and the successful pivotal phase
III (DELOS) study, the latter in patients not taking concomitant
glucocorticoids. The outcomes of the phase III DELOS study were published in
several peer-reviewed journals: Buyse et al., The Lancet 2015, 385:1748-1757;
McDonald et al., Neuromuscular Disorders 2016, 26:473-480, Buyse et al.,
Pediatric Pulmonology 2017, 52:580-515 and Mayer et al., Journal of
Neuromuscular Diseases 2017, 4: 189-198.
The intended indication for Raxone is to slow the decline of respiratory
function in patients with DMD who are currently not taking glucocorticoids. The
indication would include patients who were previously treated with
glucocorticoids or in whom glucocorticoid treatment is not tolerated or is
considered inadvisable.
About Duchenne Muscular Dystrophy
DMD is one of the most common and devastating types of muscle degeneration and
leads to progressive muscle weakness starting at an early age. DMD is a genetic,
degenerative disease that occurs almost exclusively in males with an incidence
of up to 1 in 3,500 live male births worldwide.
About Idebenone in Duchenne Muscular Dystrophy
DMD is characterized by a loss of the protein dystrophin, leading to cell
damage, impaired calcium homeostasis, elevated oxidative stress and reduced
energy production in muscle cells. This results in progressive muscle weakness,
muscle wasting, early morbidity and mortality due to respiratory failure.
Idebenone is a synthetic short-chain benzoquinone and a cofactor for the enzyme
NAD(P)H:quinone oxidoreductase (NQO1) capable of stimulating mitochondrial
electron transport, reducing and scavenging reactive oxygen species (ROS) and
supplementing cellular energy levels.
DELOS was a phase III, double-blind, placebo-controlled 52-week study which
randomized 64 patients, not taking concomitant steroids, to receive either
idebenone (900 mg/day) or matching placebo. The study met its primary endpoint,
the change from baseline in Peak Expiratory Flow (PEF), which demonstrated that
idebenone can slow the loss of respiratory function.
Idebenone was well tolerated in the DELOS study, with overall incidence of
adverse events being similar to placebo.
About Santhera
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company
focused on the development and commercialization of innovative pharmaceutical
products for the treatment of orphan mitochondrial and neuromuscular diseases.
Santhera's lead product Raxone(®) (idebenone) is authorized in the European
Union, Norway, Iceland, Liechtenstein and Israel for the treatment of Leber's
hereditary optic neuropathy (LHON). For Duchenne muscular dystrophy (DMD),
Santhera has filed a Marketing Authorization Application in the European Union
and Switzerland for DMD patients with respiratory function decline who are not
taking glucocorticoids. In collaboration with the U.S. National Institute of
Neurological Disorders and Stroke (NINDS) Santhera is developing Raxone(®) in a
third indication, primary progressive multiple sclerosis (PPMS), and omigapil
for congenital muscular dystrophy (CMD), all areas of high unmet medical need.
For further information, please visit the Company's website www.santhera.com.
Raxone(®) is a trademark of Santhera Pharmaceuticals.
For further information:
Sue Schneidhorst, Head Group Communications
Europe: +41 61 906 89 26
US: +1 646 586 2113
sue.schneidhorst(at)santhera.com
Investors:
Christoph Rentsch, Chief Financial Officer Hans Vitzthum,
LifeSci Advisors
Europe: +41 61 906 89 65 US:
+1 212 915 2568
christoph.rentsch(at)santhera.com
hans(at)lifesciadvisors.com
Disclaimer / Forward-looking statements
This communication does not constitute an offer or invitation to subscribe for
or purchase any securities of Santhera Pharmaceuticals Holding AG. This
publication may contain certain forward-looking statements concerning the
Company and its business. Such statements involve certain risks, uncertainties
and other factors which could cause the actual results, financial condition,
performance or achievements of the Company to be materially different from those
expressed or implied by such statements. Readers should therefore not place
undue reliance on these statements, particularly not in connection with any
contract or investment decision. The Company disclaims any obligation to update
these forward-looking statements.
# # #
News Release CHMP DMD:
http://hugin.info/137261/R/2134329/816556.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Santhera Pharmaceuticals Holding AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 15.09.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 560049
Anzahl Zeichen: 7782
contact information:
Town:
Liestal
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 279 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Santhera Receives Negative Opinion from the CHMP for its Marketing Authorization Application for Raxone® in DMD and Intends to Appeal this Opinion"
steht unter der journalistisch-redaktionellen Verantwortung von
Santhera Pharmaceuticals Holding AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
